CD80 and neoplasm: Using the systemic tumor model described above, we assessed the anti-tumor capacity of 19z1-CD80+ T cells expressing a control shRNA or an anti-CTLA-4 shRNA, tracked by a fluorescent reporter (Fig 4A).